Humanigen claims a Covid-19 win with lenzilumab
But the company focused on a modified intent-to-treat analysis of its pivotal trial.
Glaxo fails to win an Oscar
There might be a use for Glaxo’s anti-Covid-19 antibody otilimab in old patients, but repeating Actemra’s trick will not be easy.
Incyte’s Jakafi disappoints in severe Covid-19
As Jak inhibition takes a big knock, attention turns to other immunosuppressive mechanisms being studied in very ill Covid-19 patients.
Scanning the horizon for future Covid-19 treatments
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
